Compare Johnson & Johnson (JNJ) vs Prudential PLC (PUK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Prudential PLC — how do they compare? Johnson & Johnson trades at $261.43 (market cap $618.09B), while Prudential PLC trades at $23.92 (market cap $28.84B). The key difference: Johnson & Johnson is far larger — about 21.4× Prudential PLC's market cap, and Prudential PLC pays the higher dividend (2.33%). Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Prudential PLC for 119 Days on average.
| JNJ | PUK | |
|---|---|---|
Market Cap | $618.09B | $28.84B |
Volume | 6,050,983 | 3,531,298 |
Sector | Health | Financials |
52-Week High | $278.43 | $33.61 |
52-Week Low | $186.00 | $23.54 |
Typical Hold Time | 129 Days | 119 Days |
Enterprise Value | $646.37B | $28.38B |
Dividend Yield | 2.09% | 2.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $261.44, up 1.16% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with $94.19B revenue, 21.48% net margin, and consistent dividend payments. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with a $286.53 consensus target.
JNJ offers stable growth potential with diversified healthcare operations and robust profitability. Key risks include patent expirations, competitive pressures, and debt levels. Analyst consensus leans bullish with 52.5% buy ratings, though technical indicators suggest near-term caution. The stock presents a balanced opportunity for long-term investors seeking healthcare exposure.
Prudential Public Limited Company (PUK) trades at $23.92, up 1.61% over 24 hours, with a bearish technical signal from moving averages but oversold RSI readings. The company reported strong revenue growth to $27.39B in 2025 and a net income of $3.98B, with improving profitability margins and a low P/E of 8.4. Recent news highlights strategic shifts, including the sale of its Alexforbes stake and a focus on core markets.
The outlook is mixed: solid fundamentals and analyst 'Moderate Buy' consensus support upside, but technical weakness and earnings misses pose near-term risks. Key opportunities include capital return initiatives and cost savings; risks involve execution of strategic overhaul and emerging market exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Prudential PLC
Prudential is an Asia and Africa health and life insurance business and is focused on long-term savings. The business is increasingly focusing on digital offerings and creating strong brand equity and relationships with customers of its products through these.
Read more on PUK →
